Biosearch Announces Acquisition of European Companies DNA Technology and VitraBio
News Jul 23, 2013
Biosearch Technologies, Inc. (Biosearch) has announced that it has acquired the oligonucleotide manufacturing division of the Danish company DNA Technology A/S (DNA Technology) and German CPG manufacturer VitraBio GmbH (VitraBio).
With the acquisition of DNA Technology, Biosearch has added a highly skilled production team with a mature quality system and an established European customer base focused in the Nordic countries.
DNA Technology specializes in production of modified oligos, and will benefit from full access to the breadth of specialty modifications produced by Biosearch.
In addition, Biosearch will provide manufacturing tools and access to its substantial IP portfolio enabling DNA Technology to expand production capabilities and product offerings in order to better serve an expanding customer base.
With the acquisition of German controlled-pore glass (CPG) manufacturer VitraBio in September 2011, Biosearch gains control over VitraBio’s sophisticated CPG manufacturing technology and unique production facility, which expands its already extensive repertoire of oligo synthesis tools and processes.
In addition to continuing production of DNA/RNA synthesis supports for the research and therapeutic oligo markets, Biosearch intends to bring chemical manufacturing capabilities to VitraBio’s Steinach facility to supplement existing US production of specialty amidites and modified CPGs.
The acquisition of DNA Technology and VitraBio marks Biosearch’s increasing commitment to support European biotechnology and diagnostic markets.
Furthermore, Biosearch has secured important manufacturing redundancy for its North American operations as well as a strong base from which to grow sales, production and regulated contract manufacturing capabilities throughout Europe.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE